
Opinion|Videos|May 28, 2024
CSF Testing and Blood-based Biomarkers in Alzheimer’s Disease
Panelists review the use of CSF and blood-based biomarkers in Alzheimer's disease, discussing the role of tau as a marker of neuronal injury and its utility in staging the progression of Alzheimer's disease.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- Describe the use of CSF and blood-based biomarkers in AD.
- Which biomarkers/histopathological features are associated with different stages of Alzheimer’s disease?
- What are you using in your practice?
- What are the unmet needs?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Phase 3 Biomarker Data Shows Valiltramiprosate Reduces Plasma p-Tau217 in APOE4/4 Carriers
2
AAIC 2026 Preview: David Wolk, MD, on Biomarkers, Disease Heterogeneity, and What's Next in Alzheimer Research
3
Rethinking Clinical Trial Design and the Immune System in Multiple Sclerosis: Ahmed Obeidat, MD, PhD
4
FDA Approves At-Home Starting Dose for Lecanemab, Marking First Subcutaneous Initiation Option for Alzheimer Disease Treatment
5



















